Treace Medical Concepts, Inc. (NASDAQ: TMCI)

$2.76 ▲ +0.23 (+9.09%)

As of May 14, 2026 03:59 PM

Sector: Healthcare Industry: Medical Devices CIK: 0001630627

Market Cap 159.75 Mn

P/E -2.72

P/S 0.75

Div. Yield 0.00

Total Debt (Qtr) 57.60 Mn

Revenue Growth (1y) (Qtr) -10.22

Add ratio to table...

About

Treace Medical Concepts, Inc. is a medical technology company that designs, develops, manufactures and markets surgical solutions for the correction of bunions and related midfoot deformities. The company’s core offering is the Lapiplasty 3D Bunion Correction System, which combines instruments, implants and a surgical technique to address the three dimensional nature of the deformity. In addition to Lapiplasty, Treace markets the Adductoplasty Midfoot Correction System, minimally invasive osteotomy systems (Nanoplasty and Percuplasty), the SpeedMTP...

Treace Medical Concepts, Inc. is a medical technology company that designs, develops, manufactures and markets surgical solutions for the correction of bunions and related midfoot deformities. The company’s core offering is the Lapiplasty 3D Bunion Correction System, which combines instruments, implants and a surgical technique to address the three dimensional nature of the deformity. In addition to Lapiplasty, Treace markets the Adductoplasty Midfoot Correction System, minimally invasive osteotomy systems (Nanoplasty and Percuplasty), the SpeedMTP implant for great toe fusion, the SpeedPlate rapid compression platform, patient specific IntelliGuide instruments and a line of sterile surgical tools. The company states that bunions affect approximately 67 million Americans, of which an estimated 1.1 million are annual surgical candidates representing a total addressable market opportunity of more than five billion dollars. Approximately 450,000 surgical bunion procedures are performed in the United States every year, corresponding to a market greater than two point three billion dollars. Treace was founded with the goal of advancing the standard of care for bunion surgery and has built a portfolio of patented technologies supported by a surgeon advisory board comprising podiatrists and orthopedic foot and ankle specialists.

The company generates revenue primarily from the sale of its surgical instruments, implants and disposable procedure kits to hospitals, ambulatory surgery centers and independent surgical practitioners. Sales are conducted in the United States through a direct employee sales force that is supplemented by independent sales agencies and stocking distributors focused on foot and ankle specialists. In 2025, employee sales representatives generated approximately 80% of total revenue. Treace also offers a line of biologics and wedges such as treace allograft grafts and cortical fiber products, as well as a hammertoe PEEK fixation system. The company invests in surgeon education and training programs, including simulated surgical workshops, technical assistance in the operating room and advanced training for both new and existing surgeon customers. Treace runs a direct to patient outreach program that educates patients on the benefits and risks of its products and provides a Find a Doctor tool on its website.

Within the competitive orthopedic foot and ankle market, Treace positions itself as a specialized innovator focused exclusively on bunion and midfoot correction. It competes with large diversified medical device companies such as Stryker Corporation, Arthrex, Inc., Zimmer Biomet Holdings, Inc., DePuy Synthes (a Johnson & Johnson subsidiary) and other niche players like Paragon 28, Inc. and Nextremity Solutions. Treace differentiates itself through its patented Lapiplasty 3D technology, a growing body of peer reviewed clinical evidence demonstrating low recurrence rates and rapid recovery, and a dedicated surgeon education curriculum that includes hands on workshops and mastery webinars. The company’s intellectual property portfolio includes 95 granted U. S. patents, one exclusively licensed U. S. patent and 39 granted foreign patents as of December 31, 2025. Its strong direct sales force and surgeon support teams aim to increase product utilization per physician over time. Treace also highlights its focus on improving clinical outcomes such as early weight bearing, low nonunion rates and patient reported pain reduction as key competitive strengths.

Treace’s customers consist of orthopedic surgeons, podiatrists and foot and ankle specialists who perform bunion and midfoot procedures, as well as the hospitals and ambulatory surgery centers where those surgeries are conducted. The company does not disclose individual customer names in its filing, but its sales force targets the approximately 8,000 surgical podiatrists and 2,600 orthopedic surgeons with foot and ankle specialization in the United States. Treace supports its customers through clinical education, surgical training and a suite of sterile instruments designed to improve procedural efficiency and outcomes. The firm also provides a patient education website that helps potential surgical candidates locate trained surgeons in their local area. Additionally, the company offers a National Bunion Day initiative to raise awareness and reduce stigma associated with the condition.

Investment thesis

Bull case

Treace’s aggressive expansion of its bunion‑correction portfolio provides a unique cross‑sell engine that can unlock incremental revenue from surgeons already carrying its flagship lapoplasty line. The company has moved from a single‑technology focus to a full spectrum of five instrumented systems, including two 3‑D MIS osteotomy platforms and a great‑toe fusion system, positioning it to capture the entire patient cohort that currently disperses across multiple vendors. Because the new systems have lower ASPs than lapoplasty yet still deliver higher volume, the revenue‑mix shift is likely to broaden rather than erode overall top‑line growth, especially as the training and education arm of the sales team accelerates product familiarity. Over the next 12–18 months, the anticipated uptake of these systems, already evidenced by 20 % of surgeons adopting at least one new product in the first quarter post‑launch, should translate into sustained case volume gains that outpace the temporary dip in lapoplasty volumes.
The company’s 2025 guidance, while modest, reflects a deliberate, incremental approach to growth that mitigates over‑ambitious expectations and preserves cash reserves. The management team’s focus on reducing cash burn by 43–47 % and targeting a 32–41 % improvement in adjusted EBITDA indicates disciplined cost discipline, especially given the 8 % rise in operating expenses in 2024 was largely driven by controlled investments in medical education and restructuring. By keeping cash usage in check, Treace preserves the financial flexibility to invest in new product development and to weather any short‑term market softness without resorting to dilutive financing.
The recent launch of the next‑generation Lapaplasty Lightning platform and the Percuplasty compression screw system represents a pipeline of innovations that could deliver higher margin, more differentiated offerings in the high‑volume MTP fusion and osteotomy segments. While management has not yet disclosed specific launch dates, the announced product roadmap signals a proactive strategy to stay ahead of competitors in rapidly evolving minimally invasive foot surgery. This pipeline should bolster the company’s long‑term competitive moat and open new revenue streams that will offset any temporary lag in lapoplasty adoption.
Treace’s robust liquidity position, with $57.4 million in cash and $23.2 million in revolving credit, provides a safety cushion that reduces the need for costly external capital. The company’s high gross margins, hovering near 80 %, combined with the ability to reallocate savings from the restructuring program, ensures that the business can sustain profitability even if short‑term case volumes plateau. Investors can view the cash cushion as a buffer that enables the firm to maintain product development momentum without compromising operational execution.
The broader industry trend of increased patient and surgeon preference for minimally invasive procedures aligns with Treace’s product mix shift. By capturing a larger share of the osteotomy and fusion market, the company taps into a patient cohort that is willing to pay for quicker recovery times and less postoperative pain. As these procedures gain traction, the incremental sales from the new systems will become a more significant portion of total revenue, potentially offsetting any decline in lapoplasty volumes and driving sustainable long‑term growth.

Treace’s aggressive expansion of its bunion‑correction portfolio provides a unique cross‑sell engine that can unlock incremental revenue from surgeons already carrying its flagship lapoplasty line. The company has moved from a single‑technology focus to a full spectrum of five instrumented systems, including two 3‑D MIS osteotomy platforms and a great‑toe fusion system, positioning it to capture the entire patient cohort that currently disperses across multiple vendors. Because the new systems have lower ASPs than lapoplasty yet still deliver higher volume, the revenue‑mix shift is likely to broaden rather than erode overall top‑line growth, especially as the training and education arm of the sales team accelerates product familiarity. Over the next 12–18 months, the anticipated uptake of these systems, already evidenced by 20 % of surgeons adopting at least one new product in the first quarter post‑launch, should translate into sustained case volume gains that outpace the temporary dip in lapoplasty volumes.
The company’s 2025 guidance, while modest, reflects a deliberate, incremental approach to growth that mitigates over‑ambitious expectations and preserves cash reserves. The management team’s focus on reducing cash burn by 43–47 % and targeting a 32–41 % improvement in adjusted EBITDA indicates disciplined cost discipline, especially given the 8 % rise in operating expenses in 2024 was largely driven by controlled investments in medical education and restructuring. By keeping cash usage in check, Treace preserves the financial flexibility to invest in new product development and to weather any short‑term market softness without resorting to dilutive financing.
The recent launch of the next‑generation Lapaplasty Lightning platform and the Percuplasty compression screw system represents a pipeline of innovations that could deliver higher margin, more differentiated offerings in the high‑volume MTP fusion and osteotomy segments. While management has not yet disclosed specific launch dates, the announced product roadmap signals a proactive strategy to stay ahead of competitors in rapidly evolving minimally invasive foot surgery. This pipeline should bolster the company’s long‑term competitive moat and open new revenue streams that will offset any temporary lag in lapoplasty adoption.
Treace’s robust liquidity position, with $57.4 million in cash and $23.2 million in revolving credit, provides a safety cushion that reduces the need for costly external capital. The company’s high gross margins, hovering near 80 %, combined with the ability to reallocate savings from the restructuring program, ensures that the business can sustain profitability even if short‑term case volumes plateau. Investors can view the cash cushion as a buffer that enables the firm to maintain product development momentum without compromising operational execution.
The broader industry trend of increased patient and surgeon preference for minimally invasive procedures aligns with Treace’s product mix shift. By capturing a larger share of the osteotomy and fusion market, the company taps into a patient cohort that is willing to pay for quicker recovery times and less postoperative pain. As these procedures gain traction, the incremental sales from the new systems will become a more significant portion of total revenue, potentially offsetting any decline in lapoplasty volumes and driving sustainable long‑term growth.

Bear case

The management’s candid acknowledgment that lapoplasty case volumes have declined by roughly 7 % year‑to‑date and that the shift toward minimally invasive osteotomies has not yet translated into compensatory revenue growth raises substantive concerns about the company’s core business resilience. Even though the new systems are gaining traction, they currently sell at lower ASPs, meaning the revenue generated per procedure is smaller and may not fully offset the loss from higher‑margin lapoplasty sales. As a result, the overall revenue trajectory could remain stagnant or even contract if adoption of the new platforms does not accelerate beyond mid‑single‑digit case volume growth.
The company’s reliance on a one‑time pull‑forward benefit from distributor stocking orders—approximately $3 million in Q3—illustrates a fragile sales dynamic that may not repeat at scale. Management explicitly warned that this headwind could manifest in Q4, suggesting that revenue growth is contingent on a temporary inventory build rather than sustained market demand. If distributors choose not to maintain high inventory levels or if the market perception of the new products shifts, the company could experience a significant downturn in top‑line performance during a critical season.
Macroeconomic headwinds continue to exert pressure on elective procedures, as evidenced by the survey indicating that surgeons are deferring bunion surgeries for commercially insured patients. The company’s revenue guidance for 2025—a modest 1–2 % growth—reflects the expectation that broader consumer sentiment will remain subdued, and case volumes may not rebound swiftly. In an industry where the timing of elective surgeries is highly sensitive to economic cycles, a lingering slowdown could translate into a prolonged period of underperformance, especially if surgeons shift further toward competitors’ MIS offerings.
The Q&A revealed that while the new product suite has gained traction, the sales team’s efforts to induce lapoplasty adoption among new customers are not yet yielding measurable results. This lag in cross‑selling efficacy suggests that the company’s core high‑margin product line is not being fully leveraged as a growth engine. If lapoplasty adoption stalls, the company risks becoming overly dependent on lower‑margin MIS products, which could compress overall profitability in a highly price‑sensitive segment.
The increasing operating expenses—particularly litigation and restructuring charges—highlight ongoing legal and operational risk that could erode the company’s financial position if not managed effectively. The restructuring charge disclosed in Q3 signals significant organizational changes that may carry hidden costs, such as severance or asset write‑downs, that could impact future profitability. Additionally, the company’s reported litigation expense growth underscores potential exposure to costly disputes that could further strain margins.

The management’s candid acknowledgment that lapoplasty case volumes have declined by roughly 7 % year‑to‑date and that the shift toward minimally invasive osteotomies has not yet translated into compensatory revenue growth raises substantive concerns about the company’s core business resilience. Even though the new systems are gaining traction, they currently sell at lower ASPs, meaning the revenue generated per procedure is smaller and may not fully offset the loss from higher‑margin lapoplasty sales. As a result, the overall revenue trajectory could remain stagnant or even contract if adoption of the new platforms does not accelerate beyond mid‑single‑digit case volume growth.
The company’s reliance on a one‑time pull‑forward benefit from distributor stocking orders—approximately $3 million in Q3—illustrates a fragile sales dynamic that may not repeat at scale. Management explicitly warned that this headwind could manifest in Q4, suggesting that revenue growth is contingent on a temporary inventory build rather than sustained market demand. If distributors choose not to maintain high inventory levels or if the market perception of the new products shifts, the company could experience a significant downturn in top‑line performance during a critical season.
Macroeconomic headwinds continue to exert pressure on elective procedures, as evidenced by the survey indicating that surgeons are deferring bunion surgeries for commercially insured patients. The company’s revenue guidance for 2025—a modest 1–2 % growth—reflects the expectation that broader consumer sentiment will remain subdued, and case volumes may not rebound swiftly. In an industry where the timing of elective surgeries is highly sensitive to economic cycles, a lingering slowdown could translate into a prolonged period of underperformance, especially if surgeons shift further toward competitors’ MIS offerings.
The Q&A revealed that while the new product suite has gained traction, the sales team’s efforts to induce lapoplasty adoption among new customers are not yet yielding measurable results. This lag in cross‑selling efficacy suggests that the company’s core high‑margin product line is not being fully leveraged as a growth engine. If lapoplasty adoption stalls, the company risks becoming overly dependent on lower‑margin MIS products, which could compress overall profitability in a highly price‑sensitive segment.
The increasing operating expenses—particularly litigation and restructuring charges—highlight ongoing legal and operational risk that could erode the company’s financial position if not managed effectively. The restructuring charge disclosed in Q3 signals significant organizational changes that may carry hidden costs, such as severance or asset write‑downs, that could impact future profitability. Additionally, the company’s reported litigation expense growth underscores potential exposure to costly disputes that could further strain margins.

Breakdown of Revenue (2025)

Inventory Breakdown of Revenue (2025)

Peer comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	145.93 Bn	23.33	3.23	34.05 Bn
2	SYK	Stryker Corp	115.71 Bn	34.62	4.58	14.72 Bn
3	MDT	Medtronic plc	97.69 Bn	21.17	2.75	28.07 Bn
4	BSX	Boston Scientific Corp	78.71 Bn	22.00	3.82	11.03 Bn
5	EW	Edwards Lifesciences Corp	47.63 Bn	44.75	7.85	0.60 Bn
6	PHG	Koninklijke Philips Nv	29.38 Bn	13,009.40	1.46	8.07 Bn
7	DXCM	Dexcom Inc	22.72 Bn	24.58	4.72	-
8	STE	STERIS plc	20.71 Bn	29.06	3.55	1.90 Bn

Research Tools